The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
03
2020
revised:
16
04
2020
accepted:
21
04
2020
pubmed:
2
5
2020
medline:
18
9
2020
entrez:
2
5
2020
Statut:
ppublish
Résumé
With licensure of extended half-life (EHL) factor products and the changing landscape of available hemophilia products, patients and providers have options for less treatment-intense prophylaxis. The impact of these products in clinical practice to date remains understudied. We aimed to quantify the use of EHL products in prophylaxis in the US using the ATHN-dataset, a database of 145 ATHN-affiliated hemophilia treatment centers (HTCs). Further, we aimed to quantify the impact of EHL on key hemophilia indicators including annualized bleed rates (ABRs), hemophilia joint health scores (HJHS) and quality of life (QOL) metrics. The use of EHL vs standard half-life (SHL) products in severe hemophilia was compared between June 2018 and March 2019 using the ATHN-dataset. A cohort of patients was also recruited from seven participating HTCs in order to compare ABR, HJHS and QOL between product classes. By March 2019 the number of individuals with severe Hemophilia A (SHA) receiving EHLs remained relatively stable (28.4%), whereas the number of prescribed non-factor products increased to 7.1%, with a diminishing majority of patients (64.0%) continuing to receive SHLs. The majority of patients with severe hemophilia B (SHB) received treatment with EHLs including 57.5% by March 2019. There was a trend toward lower ABR with use of EHLs in SHA and SHB, although this did not result in improved HJHS nor QOL. EHL use in the United States in severe hemophilia continues to increase, although at a slower rate in SHA with the availability of non-factor therapy. The impact of the EHL therapies in clinical practice should continue to be examined prospectively.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
960-965Informations de copyright
© 2020 Wiley Periodicals, Inc.© 2020 Wiley Periodicals, Inc.
Références
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis vs episodic treatment to prevent joint disease in boys with severe hemophilia. NEJM. 2007;357:L535-L544.
Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700-710.
Valentino LA, Mamonov V, Hellman A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatment in hemophilia A management. J Thromb Haemost. 2012;10:359-367.
Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Europ J of Haemo. 2012;88:329-335.
Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1999;232:25-32.
Srivastava A, Brewer AK, Mauser-Bunschoten EP. Guidelines for the management of hemophilia. Haemophilia. 2013. Epub 6 July19(1):e1-e47. https://doi.org/10.1111/j.1365-2516.2012.02909.x.
ATHN Research Report 2015. http://athn.org/files/resources/ATHN-dataset/ATHN20Research20Report20Brief202015-06-30.pdf. Accessed September 2015.
Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor FVIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031-3037.
Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended interval dosing maintains low bleeding rates and correlates with von Willebrand Factor levels. J Thromb Haemost. 2014;12:1788-1800.
Croteau SE, Cheng D, Cohen AJ, et al. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe hemophilia. Haemophilia. 2019;25(4):668-675.
Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidelines from the UKHCDO. Haemophilia. 2016;22(4):487-498.
Keepanasseril A, Stoffman J, Bouskill V, et al. Switching to extended half-life products in Canada. Haemophilia. 2017;23(4):e365-e367.